[ 18 F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab.

Alberto Signore Chiara LauriMaria Paola BianchiSabrina PellicciaAndrea LenzaSimone TettiMaria Luisa MartiniGabriele FranchiFabio TrapassoLuciano De BiaseAntonio AcetiAgostino Tafuri

Published in: Journal of personalized medicine (2022)

F]FDG PET/CT. Our results confirm that interleukin-6 (IL6) has a role in the COVID-19 disease and that anti-cytokine treatment can also be performed in patients with lymphoproliferative disorders.

Keyphrases

sars cov
epstein barr virus
end stage renal disease
newly diagnosed
coronavirus disease
ejection fraction
chronic kidney disease
respiratory syndrome coronavirus
prognostic factors
juvenile idiopathic arthritis
rheumatoid arthritis patients
patient reported outcomes
systemic lupus erythematosus